Working… Menu

A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC (AXEPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01996306
Recruitment Status : Completed
First Posted : November 27, 2013
Last Update Posted : January 8, 2019
Information provided by (Responsible Party):
Epidemiological and Clinical Research Information Network